The European Medicines Agency has begun evaluating an approval application from GlaxoSmithKline and Vir for their monoclonal antibody, Xevudy (sotrovimab), for treating adults and adolescents with COVID-19 who do not require supplemental oxygen therapy and are at increased risk of progressing to severe disease.
The agency’s human drugs committee, the CHMP, has also issued a scientific opinion to EU member states wanting to grant...








